Clarithromycin in adult-onset Still’s disease: a study of 6 cases

被引：0
作者：
Gianantonio Saviola
Maurizio Benucci
Lul Abdi-Ali
Paola Baiardi
Mariangela Manfredi
Mariarosaria Bucci
Giuseppe Cirino
机构：
[1] Salvatore Maugeri Foundation IRCCS,Rheumatology and Rehabilitation Unit
[2] New Hospital S. Giovanni di Dio,Rheumatology Unit
[3] Salvatore Maugeri Foundation IRCCS and University of Pavia,Methodology Unit, Consorzio Valutazioni Biologiche e Farmacologiche
[4] New Hospital S. Giovanni di Dio,Immunology and Allergology Laboratory Unit
[5] University of Naples–Federico II,Department of Experimental Pharmacology, Faculty of Pharmacy
来源：
Rheumatology International | 2010年 / 30卷
关键词：
AOSD; Adult-onset Still’s disease; Rheumatic disease; Clarithromycin; Macrolide antibiotics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Adult-onset Still’s disease (AOSD) is a rare rheumatological condition characterized by an acute systemic involvement. There are no treatment guidelines. Glucocorticoids (GC), methotrexate (MTX), cyclosporin A and biologic agents have been successfully used, often in association. We treated six cases of AOSD with clarithromycin (CM) in combination with low-mild dose of GC and MTX. Four of them were not responsive to high-dose GC added to DMARDs, while two of them were treated with low-mild dose of GC added to CM from the beginning. CM, 500 mg b.i.d., was added to a mild-low dose of GC and to MTX. The dose of the drugs was reduced (and stopped where possible) following clinical and laboratory parameters. ACR criteria were used to assess clinical improvement. At 6 months 5 patients reached ACR 70% and could stop any therapy in 6–18 months; 1 continued chronic therapy with low-dose GC added to CM and MTX to maintain ACR 50%. CM can be a useful drug for the treatment of AOSD, even in patients not responsive to high-dose GC and DMARDs. No definitive conclusion can be drawn based on the present study.
引用
收藏
页码：555 / 560
页数：5
相关论文
共 84 条
[1]  
Efthimiou P(2006)Diagnosis and management of adult’s onset Still’s disease Ann Rheum Dis 65 564-572
[2]  
Paik PK(2008)Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome Arthritis Rheum 58 1521-1527
[3]  
Bielory L(1992)Preliminary criteria for classification of adult onset Still’s disease J Rheumatol 19 424-430
[4]  
Fardet L(2005)Tumor necrosis factor α blocking agents in refractory adult Still’s disease: an observational study of 20 cases Ann Rheum Dis 64 262-266
[5]  
Coppo P(1997)Cyclosporin A in the treatment of adult onset Still’s disease J Rheumatol 24 1582-1587
[6]  
Kettaneh A(1999)Corticosteroid sparing effect of low dose methotrexate treatment in adult Still’s disease J Rheumatol 26 373-378
[7]  
Dehoux M(1998)Intravenous immunoglobulin in adult onset Still’s disease refractory to non-steroidal anti-inflammatory drugs Clin Exp Rheumatol 16 295-298
[8]  
Cabane J(2006)Pathogenesis and management of adult-onset Still’s disease Semin Arthritis Rheum 36 144-152
[9]  
Lambrotte O(2002)Etanercept in the treatment of adult patients with Still’s disease Arthritis Rheum 46 1171-1176
[10]  
Yamaguchi M(2001)Successful treatment of a small cohort of patients with adult onset of Still’s disease with infliximab: first experiences Ann Rheum Dis 60 55-57
123456789